Avalo Therapeutics, Inc. Common Stock
AVTXStock
$17.88+286.46%52W
Market Cap$948.02M
P/E—
Div yield—
Beta0.75
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)0.04%
Price vs S&P 500 (4W)28.85%
VGM Score28.74
Market Capitalization$948.02M
Earnings Surprise History
Q1 26-0.98est. -1.05
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.35
4.35
4.33
4.37
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVTXAvalo Therapeutics, Inc. Common Stock | F | F | B | $17.88 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Avalo Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins to treat immune dysregulation disorders. The company's lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody targeting inflammatory diseases. Additional pipeline candidates include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).